Thursday, June 4

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Hall 4/5

THROMBOCYTOPENIAS

Chair: B Godeau (CHU Henri Mondor, Créteil, France)

• INTRODUCTION
  B Godeau (CHU Henri Mondor, Créteil, France),
  F Rodeghiero (San Bortolo Hospital, Vicenza, Italy)
• INTERNATIONAL PRIMARY IMMUNE THROMBOCYTOPENIA
  GUIDELINE: DIAGNOSIS AND MANAGEMENT OF ADULT ITP
  D Provan (Barts and the London School of Medicine and Dentistry, London, United Kingdom)
• HEMORRHAGIC SCORE FOR ITP IN ADULTS AND CHILDREN
  M Michel (Créteil, France Institute,requested)
• THROMBOSIS AND ITP
  M Ruggeri (San Bortolo Hospital, Vicenza, Italy)
• FATIGUE AND ITP
  J Bussel (Weill Cornell Medical College of Cornell University, New York, USA)

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Hall 7

MYELOPROLIFERATIVE DISORDERS

Chair: H Pahl (Center for Clinical Research / University Hospital Freiburg, Freiburg, Germany)

• APOPTOSIS INDUCED BY JAK2 INHIBITION IS MEDIATED BY BIM AND ENHANCED BY THE BH3 MIMETIC ABT-737 IN JAK2 MUTANT HUMAN ERYTHROID CELLS
  D Tenen (Harvard Medical School, Boston, USA)
• APLIDIN AMELIORATES THE MYELOPROLIFERATIVE DISORDERS PHENOTYPE IN THE GATA-LO MOUSE MODEL
  A Migliaccio (Mount Sinai School of Medicine, New York, USA)
• ONCOGENIC JAK2V617F REQUIRES AN INTACT SH2 DOMAIN FOR CONSTITUTIVE ACTIVATION AND INDUCTION OF A MYELOPROLIFERATIVE DISEASE IN MICE
  J Duyster (Klinikum Rechts der Isar, Technische Universität Munich, Munich, Germany)
  

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Hall 9

MYELODYSPLASTIC SYNDROMES

Chair: P Fenaux (Hôpital Avicenne, Paris, France)
E Hellström-Lindberg (Karolinska Institutet, Stockholm, Sweden)

• NEW ADVANCES WITH SNP ARRAYS IN MYELODYSPLASTIC SYNDROME
  A Mohmadali (King's College, London, United Kingdom)

• LINEAGE SPECIFIC CHANGE IN DNA-METHYLATION PATTERN IN DIFFERENTIATING HEMATOPOIETIC CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME
  O Hopfer (Charité Hospital, Berlin, Germany)
• TET2, A NEW TUMOR SUPPRESSOR GENE FREQUENTLY MUTATED IN MYELODYSPLASTIC SYNDROMES.
  O Kosmider (Hôpital Cochin, Paris, France)
• STEM CELLS IN 5Q- SYNDROME
  C Scharenberg (Karolinska Institutet, Stockholm, Sweden)
• CLINICAL PERSPECTIVES IN HIGHER RISK MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA WITH DEL 5Q
  L Ades (Hôpital Avicenne, Paris, France)

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Salon Koch

EUROFLOW

Chair: J van Dongen (Erasmus Medical Center, Rotterdam, The Netherlands)

• INTRODUCTION ON EUROFLOW ACTIVITIES
  J van Dongen (Erasmus Medical Center, Rotterdam, The Netherlands)
• FLOW CYTOMETRIC DETECTION OF FUSION GENE ABERRATIONS AT THE PROTEIN LEVEL
  E Dekking (Erasmus Medical Center, Rotterdam, The Netherlands)
• TECHNICAL ASPECTS OF EUROFLOW IMMUNOSTAINING PROTOCOLS: INSTRUMENT SETTINGS, FLUOROCHROME CHOICE, STANDARDIZATION
  T Kalina (Charles University Prague, 2nd Medical School, Prague, Czech Republic)
• EUROFLOW 8-COLOR IMMUNOSTAINING PROTOCOLS FOR DIAGNOSIS AND CLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIAS
  L Lhermitte (Hôpital Necker-Enfants Malades, Paris, France)
• EUROFLOW 8-COLOR IMMUNOSTAINING PROTOCOLS FOR DIAGNOSIS AND CLASSIFICATION OF MATURE B-LINEAGE MALIGNANCIES
  S Boettcher (University of Schleswig-Holstein -Campus Kiel, Kiel, Germany)
• CONCLUSIONS AND DISCUSSION
  A Orfao (Centro de Investigación del Cáncer, Salamanca, Spain)

SCIENTIFIC WORKING GROUP
18:30 – 20:00, Salon Langenbeck

CHRONIC MYELOID LEUKEMIA

Chair: J Goldman (Hammersmith Hospital, London, United Kingdom)

• LOSS OF MICRORNA EXPRESSION CONTRIBUTES TO DISEASE
  PROGRESSION
  D Perrotti (The Ohio State University, Columbus, Ohio)
• PROGNOSTIC SIGNIFICANCE OF IKZF1 (IKAROS) AND PAX5 REARRANGEMENTS IN ADULT BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
  I Iacobucci (Institute of Hematology and Medical Oncology "Seràgnoli", Bologna, Italy)
• BCL6 PROMOTES LEUKEMIA STEM CELL SELF-RENEWAL IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA AND CHRONIC MYELOID LEUKEMIA
  M Muschen (University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California)

• LESSONS FROM PH-NEGATIVE CHRONIC MYELOID LEUKEMIA
  N Cross (Wessex Regional Genetics Laboratory, Salisbury,
  United Kingdom)

SCIENTIFIC WORKING GROUP
18:30 – 20:00, Salon Sauerbruch

MULTIPLE MYELOMA

Chair: P Sonneveld (Erasmus Medical Center, Rotterdam, The Netherlands)

• BIOINFORMATICS: WHICH ANALYSIS OPTIONS ARE CURRENTLY AVAILABLE FOR GEP ANALYSIS?
  A Luca (Fondazione Ospedale Maggiore Policlinico MaRe, IRCCS, Milan, Italy),
  A Neri (Fondazione Ospedale Maggiore Policlinico MaRe, IRCCS, Milan, Italy)
• CLASSIFIERS CURRENTLY BEING DEVELOPED IN MULTIPLE MYELOMA
  M van Duin (Erasmus Medical Center, Rotterdam, The Netherlands),
  P Sonneveld (Erasmus Medical Center, Rotterdam, The Netherlands)
• CLASSIFIERS PREDICTING RESPONSE TO THERAPY
  M Boegsted (Aalborg Hospital, Aarhus University, Aalborg, Denmark),
  H Johnsen (Aalborg Hospital, University Aarhus, Aalborg, Denmark)
• CROSS-VALIDATION OF CLASSIFIERS IN MULTIPLE MYELOMA – WHICH PARAMETERS ARE IMPORTANT
  N Dickens (Institute of Cancer Research, Sutton, United Kingdom),
  G Morgan (The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, London, United Kingdom)
• SUMMARY AND EMN STRATEGIES
  H Johnsen (Aalborg Hospital, University Aarhus, Aalborg, Denmark)

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Salon Virchow

GRANULOCYTE AND MONOCYTE DISORDERS

Chair: H Papadaki (University of Crete, Heraklion, Greece)

• THE TRANSCRIPTIONAL CONTROL OF GRANULOCYTIC DIFFERENTIATION?
  K Theilgaard (University of Copenhagen, Copenhagen, Denmark)
• GRANULOCYTE COLONY-STIMULATING FACTOR AND ITS RECEPTOR IN NORMAL AND ABNORMAL GRANULOPOIESIS
  I Touw (Erasmus University Medical Center, Rotterdam, The Netherlands)
• ESTABLISHMENT OF A CONSENSUS FOR THE DIAGNOSTIC WORKUP OF NEUTROPENIAS? CONGENITAL NEUTROPENIAS
  J Palmblad (Karolinska Institutet, Stockholm, Sweden)
• ESTABLISHMENT OF A CONSENSUS FOR THE DIAGNOSTIC WORKUP OF NEUTROPENIAS? – AQUIRED NEUTROPENIAS
  H Papadaki (University of Crete, Heraklion, Greece)

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Salon Columbus

QUALITY OF LIFE AND SYMPTOMS

Chair: C Cleeland (MD Anderson Cancer Center, Houston, USA)

• PRO OUTCOMES: PROPER APPLICATIONS IN CLINICAL HEMATOLOGY
  A Novik (National Medical Surgical Center, Moscow, Russian Federation)
• QOL ASSESSMENT IN PALLIATIVE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
  S Salek (Cardiff University, Cardiff, United Kingdom)
• DISCUSSION OF THE PROJECT: PRACTICAL GUIDELINES FOR HEMATOLOGISTS ON QOL ASSESSMENT IN HEMATOLOGICAL MALIGNANCIES
  T Ionova (National Medical Surgical Center, St. Petersburg, Russian Federation)
• DISCUSSION: COLLABORATION WITH ANOTHER WGS

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Salon Lilienthal

PHARMACOKINETIC, PHARMACOGENETIC & PHARMACODYNAMICS

Chair: M Hassan (Karolinska Institutet, Stockholm, Sweden)

• THE PHARMACOKINETICS AND PHARMACODYNAMICS OF COLD AND 131I LABELED RITUXIMAB IN PATIENTS WITH B-CELL NON HODGKIN'S LYMPHOMA
  L Tran (Nederlands Kanker Instituut & Antonie van Leeuwenhoek Hospital, Amsterdam, The Netherlands)
• ASSESSMENT OF PROTHROMBIN GENE MUTATION 20210 IN PATIENTS WITH ACUTE DEEP VENOUS THROMBOSIS NOT RESPONDERS TO ORAL WARFARIN THERAPY
  F Attia (Suez Canal University, Suez Canal, Egypt)
• MECHANISMS OF RESISTANCE TO NUCLEOSIDE ANALOGUE IN HEMATOLOGICAL MALIGNANCIES
  F Albertioni (Karolinska Institutet, Stockholm, Sweden)
• THERAPEUTIC DRUG MONITORING IS AN IMPORTANT FACTOR DURING IV BUSULFAN TREATMENT
  R Malär (Zurich University Hospital, Zurich, Switzerland)
• ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN EHRLICH ASCITES CARCINOMA: MODULATORY EFFECTS OF THALIDOMIDE, ROFECOXIB AND CAPTOPRIL
  M El Azab (Suez Canal University, Suez Canal, Egypt)

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Room 28/29

RED CELL AND IRON

Chair: M Cappellini (Mangiagalli Regina Elena Foundation IRCCS, University of Milan, Milan, Italy)

• IRON-REFRACTORY, IRON-DEFICIENCY ANEMIA (IRIDA)
  C Beaumont (INSERM U773 –CRB3, Paris, France)
• NEW INSIGHTS IN ALPHA GLOBIN GENES REGULATION
  D Higgs (University of Oxford, Oxford, United Kingdom)

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Room 36/37

ERIC

Chair: E Kimby (Karolinska Institutet, Stockholm,Sweden),
E Montserrat (Hospital Clinic Barcelona, City, Spain)

• INTRODUCTION
  F Caligaris-Cappio (University Scientific Institute San Raffaele, Milan, Italy)
• B-CELL RECEPTOR EPITOPE PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA
  M Binder (Universitätsklinik Hamburg-Eppendorf, Hamburg, Germany)
• THE ROLE OF TUMOR SUPPRESSOR PTEN IN THE INTERACTION BETWEEN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND THE LYMPHOID MICROENVIRONMENT
  M Shehata (Medical University, Vienna, Austria)
• THE ROLE OF CD44 SIGNALLING IN THE INTERACTION WITH THE MICROENVIRONMENT
  A Wiestner (National Institutes of Health, Bethesda, USA)
• IMPACT OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ON T-CELLS IN THE TUMOR MICROENVIRONMENT
  A Ramsay (Institute of Cancer, London, United Kingdom)